Context X-linked hypophosphatemia (XLH) is characterized by excess fibroblast growth
factor 23 (FGF23), hypophosphatemia, skeletal abnormalities, and growth impairment. We …

Burosumab, a fully human monoclonal antibody to FGF23, is the only approved treatment for
X-linked hypophosphatemia (XLH), a rare genetic disorder characterized by renal …

Background X-linked hypophosphatemia (XLH) is a rare multisystemic disease with a
prominent musculoskeletal phenotype. We aim here to improve understanding of the …

In X‐linked hypophosphatemia (XLH), inherited loss‐of‐function mutations in the PHEX
gene cause excess circulating levels of fibroblast growth factor 23 (FGF23), leading to …

Purpose In X-linked hypophosphatemia (XLH), excess fibroblast growth factor-23 causes
hypophosphatemia and low calcitriol, leading to musculoskeletal disease with clinical …

Abstract Context: X-Linked hypophosphatemia (XLH) is characterized by renal phosphate
wasting, with inappropriately low or normal serum 1, 25-dihydroxyvitamin D concentrations …

X-linked hypophosphatemia (XLH) is a rare, hereditary, progressive musculoskeletal
disease that often causes pain and short stature, as well as decreased physical function …

X-linked hypophosphatemia (XLH) is the most common genetic form of hypophosphatemic
rickets and osteomalacia. In this disease, mutations in the PHEX gene lead to elevated …

In adults with X‐linked hypophosphatemia (XLH), excess FGF23 impairs renal phosphate
reabsorption and suppresses production of 1, 25‐dihydroxyvitamin D, resulting in chronic …

Background X-linked hypophosphatemia is characterized by increased secretion of
fibroblast growth factor 23 (FGF-23), which leads to hypophosphatemia and consequently …